Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.
- Mechanism
- Curator reviewed
Oxibendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
- Primary indication
- Investigated for use/treatment in infectious and parasitic disease (unspecified) and pediatric indications.Curator reviewed
- Formula / weight
- C12H15N3O3 · 249.2658 g/mol (avg)
- Code names
- SK&F-30310
Resolves to
RAOCRURYZCVHMG-UHFFFAOYSA-NSMILESCCCOC1=CC2=C(C=C1)N=C(NC(=O)OC)N2What you can answer from here — as of March 06, 2025
Which drugs share a target with Oxibendazole, and which of those have an active Phase 3 trial?